Buys | $17,745,000 | 1 | 5 |
Sells | $248,003 | 18 | 95 |
Tempus AI, Inc. | 10 percent owner | 1 | $17.75M | 0 | $0 | $17.75M |
Moore Stephen Michael | SVP and Chief Legal Officer | 0 | $0 | 5 | $22,826 | $-22,826 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 0 | $0 | 6 | $34,336 | $-34,336 |
Tachibana Aaron | CFO AND COO | 0 | $0 | 6 | $48,577 | $-48,577 |
Hall Christopher M | PRESIDENT AND CEO | 0 | $0 | 1 | $142,263 | $-142,263 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT …
Over the last 12 months, insiders at Personalis, Inc. have bought $17.75M and sold $248,003 worth of Personalis, Inc. stock.
On average, over the past 5 years, insiders at Personalis, Inc. have bought $20.12M and sold $19.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Tempus AI, Inc. (10 percent owner) — $17.75M.
The last purchase of 3,500,000 shares for transaction amount of $17.75M was made by Tempus AI, Inc. (10 percent owner) on 2024‑08‑16.
2025-01-28 | Sale | Tachibana Aaron | CFO AND COO | 708 0.001% | $5.79 | $4,099 | -13.97% | |
2025-01-28 | Sale | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 519 0.0008% | $5.79 | $3,005 | -13.97% | |
2024-12-16 | Sale | Tachibana Aaron | CFO AND COO | 6,865 0.0098% | $3.82 | $26,224 | +39.35% | |
2024-12-16 | Sale | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 4,834 0.0069% | $3.82 | $18,466 | +39.35% | |
2024-12-16 | Sale | Moore Stephen Michael | SVP and Chief Legal Officer | 1,513 0.0022% | $3.82 | $5,780 | +39.35% | |
2024-11-18 | Sale | Tachibana Aaron | CFO AND COO | 1,307 0.002% | $3.79 | $4,954 | +34.68% | |
2024-11-18 | Sale | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 921 0.0014% | $3.79 | $3,491 | +34.68% | |
2024-11-18 | Sale | Moore Stephen Michael | SVP and Chief Legal Officer | 1,693 0.0025% | $3.79 | $6,416 | +34.68% | |
2024-11-01 | Sale | Hall Christopher M | PRESIDENT AND CEO | 26,443 0.0527% | $5.38 | $142,263 | -6.09% | |
2024-08-16 | Tempus AI, Inc. | 10 percent owner | 3.5M 7.8698% | $5.07 | $17.75M | -15.69% | ||
2024-07-30 | Sale | Tachibana Aaron | CFO AND COO | 742 0.0014% | $2.97 | $2,204 | +60.10% | |
2024-07-30 | Sale | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 524 0.001% | $2.97 | $1,556 | +60.10% | |
2024-06-17 | Sale | Tachibana Aaron | CFO AND COO | 7,176 0.0134% | $1.29 | $9,257 | +270.54% | |
2024-06-17 | Sale | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 5,055 0.0094% | $1.29 | $6,521 | +270.54% | |
2024-06-17 | Sale | Moore Stephen Michael | SVP and Chief Legal Officer | 1,585 0.003% | $1.29 | $2,045 | +270.54% | |
2024-05-17 | Sale | Tachibana Aaron | CFO AND COO | 1,333 0.0026% | $1.38 | $1,840 | +230.00% | |
2024-05-17 | Sale | Chen Richard | CHIEF MEDICAL OFFICER AND EVP | 940 0.0018% | $1.38 | $1,297 | +230.00% | |
2024-05-17 | Sale | Moore Stephen Michael | SVP and Chief Legal Officer | 1,731 0.0033% | $1.38 | $2,389 | +230.00% | |
2024-04-30 | Sale | Moore Stephen Michael | SVP and Chief Legal Officer | 4,523 0.0083% | $1.37 | $6,197 | +203.40% | |
2024-03-01 | MYERS WOODROW A JR | director | 10,000 0.0206% | $1.67 | $16,700 | +127.22% |
Tempus AI, Inc. | 10 percent owner | 12718800 14.4101% | $46.17M | 1 | 0 | |
Lightspeed Venture Partners Select IV, L.P. | director | 1774240 2.0102% | $6.44M | 3 | 0 | +58.12% |
LUDLUM KEN | director | 30000 0.034% | $108,900.00 | 1 | 1 | <0.0001% |
MYERS WOODROW A JR | director | 26116 0.0296% | $94,801.08 | 1 | 0 | +127.22% |
RICCI PAUL | director | 20000 0.0227% | $72,600.00 | 1 | 0 | <0.0001% |
Increased Positions | 57 | +56.44% | 26M | +87.77% |
Decreased Positions | 42 | -41.58% | 3M | -11.65% |
New Positions | 33 | New | 23M | New |
Sold Out Positions | 7 | Sold Out | 324,723 | Sold Out |
Total Postitions | 116 | +14.85% | 52M | +76.12% |
Merck & Co., Inc. | $58,146.00 | 19.78% | 14.04M | +14M | New | 2024-12-31 |
Lightspeed Management Company, L.L.C. | $33,785.00 | 11.49% | 8.16M | +8M | New | 2024-12-31 |
Ark Investment Management Llc | $28,050.00 | 9.54% | 6.78M | -310,088 | -4.38% | 2024-12-31 |
Aigh Capital Management Llc | $15,728.00 | 5.35% | 3.8M | -200,000 | -5% | 2024-12-31 |
Blackrock, Inc. | $12,234.00 | 4.16% | 2.96M | +39,487 | +1.35% | 2024-12-31 |
Vanguard Group Inc | $7,182.00 | 2.44% | 1.73M | -235,711 | -11.96% | 2024-12-31 |
Millennium Management Llc | $5,454.00 | 1.86% | 1.32M | -1M | -45.91% | 2024-12-31 |
Blue Water Life Science Advisors, Lp | $4,690.00 | 1.6% | 1.13M | +132,900 | +13.29% | 2024-12-31 |
Renaissance Technologies Llc | $3,812.00 | 1.3% | 920,868 | -10,243 | -1.1% | 2024-12-31 |
Susquehanna International Group, Llp | $3,615.00 | 1.23% | 873,097 | +718,336 | +464.16% | 2024-12-31 |